Volume 20 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(7): 1109-1112
XIAO Xin, SHENG Xiao-an, SHI Xian-feng, DONG Juan-juan, XU Juan, WANG Chao. Clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy on advanced cervical cancer and influence of serum heat-shock protein 90α expression[J]. Chinese Journal of General Practice, 2022, 20(7): 1109-1112. doi: 10.16766/j.cnki.issn.1674-4152.002535
Citation: XIAO Xin, SHENG Xiao-an, SHI Xian-feng, DONG Juan-juan, XU Juan, WANG Chao. Clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy on advanced cervical cancer and influence of serum heat-shock protein 90α expression[J]. Chinese Journal of General Practice, 2022, 20(7): 1109-1112. doi: 10.16766/j.cnki.issn.1674-4152.002535
shu

Clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy on advanced cervical cancer and influence of serum heat-shock protein 90α expression

doi: 10.16766/j.cnki.issn.1674-4152.002535

  • Department of Oncology, Chaohu Hospital of Anhui Medical University, Hefei, Anhui 238000, China

Funds:

 AHWJ2021b018

  • Received Date: 2021-11-12
    Available Online: 2022-09-23
    Abstract
  •   Objective  To investigate the clinical efficacy of hyperthermia combined with concurrent chemoradiotherapy in patients with advanced cervical and endocervical cancer (CESC), the changes in serum heat-shock protein 90α (HSP90α) expression before and after treatment and the value of predicting the therapeutic effect.  Methods  A total of 80 patients with advanced CESC who were admitted to Chaohu Hospital Affiliated to Anhui Medical University from January 2017 to June 2019 were selected as the research subjects. Amongst then, 40 patients who were treated with simple concurrent chemoradiotherapy were included in the control group. On the basis of the control group, 40 patients with combined hyperthermia were included in the study group. The short-term efficacy and toxicity between the two groups were compared and the changes in serum HSP90α indices in patients before and after treatment were detected.  Results  The total effective rate of the study group was 87.5%, which was significantly better than that of the control group (65.0%), and the difference was statistically significant (P < 0.05). The 2-year survival rate of the study group was significantly higher than that of the control group (P < 0.05). By contrast, no significant difference was found in the incidence of adverse reactions between the two groups (all P>0.05). In patients, the difference in the comparison of HSP90α changes before and after treatment was statistically significant (P < 0.05).  Conclusion  Hyperthermia combined with concurrent chemoradiotherapy could significantly improve the short-term curative effect in patients without significantly increasing the side effects of treatment and improve their 2-year overall survival rate. The expression of serum HSP90α decreased significantly in patients with middle-advanced CESC who have been effectively treated and the curative effect is good, hence worthy of promotion.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
    [2]
    RODEN R, STERN P L. Opportunities and challenges for human papillomavirus vaccination in cancer[J]. Nat Rev Cancer, 2018, 18(4): 240-254. doi: 10.1038/nrc.2018.13
    [3]
    WANG R J, PAN W, JIN L, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge[J]. Cancer Lett, 2020, 471: 88-102. doi: 10.1016/j.canlet.2019.11.039
    [4]
    SHRESTHA A D, NEUPANE D, VEDSTED P, et al. Cervical cancer prevalence, incidence and mortality in low and middle income countries: A systematic review[J]. Asian Pac J Cancer Prev, 2018, 19(2): 319-324.
    [5]
    肖群, 方燕飞, 孔于兰. 同步放化疗与单纯放疗对中晚期宫颈癌患者的有效性及安全性比较[J]. 中华全科医学, 2018, 16(11): 1813-1815. doi: 10.16766/j.cnki.issn.1674-4152.000493

    XIAO Q, FANG Y F, KONG Y L. Comparison of the efficacy and safety of concurrent chemoradiotherapy and radiotherapy alone in patients with advanced cervical and endocervical cancer[J]. Chinese Journal of General Practice, 2018, 16(11): 1813-1815. doi: 10.16766/j.cnki.issn.1674-4152.000493
    [6]
    邹金金, 刘定义, 刘鸿, 等. 新辅助放化疗联合热疗对进展期直肠癌的应用效果研究[J]. 中外医学研究, 2019, 17(1): 24-25. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY201901011.htm

    ZOU J J, LIU D J, LIU H, et al. Study on the effect of neoadjuvant chemoradiotherapy combined with hyperthermia on advanced rectal cancer[J]. Research on Chinese and Foreign Medicine, 2019, 17(1): 24-25. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY201901011.htm
    [7]
    郝永杰, 邓军吉, 崔传水, 等. 热疗联合同步放化疗治疗局部晚期非小细胞肺癌疗效观察[J]. 医学食疗与健康, 2020, 18(12): 41-43. https://www.cnki.com.cn/Article/CJFDTOTAL-YXSL202012028.htm

    HAO Y J, DENG J J, CUI C S, et al. Curative effect observation of hyperthermia combined with concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer[J]. Medical Diet and Health, 2020, 18(12): 41-43. https://www.cnki.com.cn/Article/CJFDTOTAL-YXSL202012028.htm
    [8]
    LANG B J, GUERRERO-GIMÉNEZ M E, PRINCE T L, et al. Heat shock proteins are essential components in transformation and tumor progression: Cancer cell intrinsic pathways and beyond[J]. Int J Mol Sci, 2019, 20(18): 4057.
    [9]
    EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
    [10]
    OEI A L, KOK H P, OEI S B, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer[J]. Adv Drug Deliv Rev, 2020, 163: 84-97. DOI: 10.1016/j.addr.2020.01.003.
    [11]
    HARIMA Y, OHGURI T, IMADA H, et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer[J]. Int J Hyperthermia, 2016, 32(7): 801-808. doi: 10.1080/02656736.2016.1213430
    [12]
    陈剑萍, 叶柳青, 于爱军, 等. 多种肿瘤标志物在宫颈癌诊断中的临床应用分析[J]. 中国卫生检验杂志, 2017, 27(17): 2533-2535. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201717030.htm

    CHEN J P, YE L Q, YU A J, et al. Analysis of clinical application of various tumor markers in the diagnosis of cervical and endocervical cancer[J]. Chinese Journal of Health Laboratory Technology, 2017, 27(17): 2533-2535. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201717030.htm
    [13]
    BOUDESCO C, CAUSE S, JEGO G, et al. Hsp70: A cancer target inside and outside the cell[J]. Methods Mol Biol, 2018, 1709: 371-396.
    [14]
    SOUDRY E, STERN S S, HARDY B, et al. Heat shock proteins Hsp90, Hsp70 and GRP78 expression in medullary thyroid carcinoma[J]. Ann Diagn Pathol, 2017, 26(6): 52-56.
    [15]
    WU J M, LIU T N, RIOS Z, et al. Heat shock proteins and cancer[J]. Trends pharmacol Sci, 2017, 38(3): 226-256. doi: 10.1016/j.tips.2016.11.009
    [16]
    LEE Y C, CHANG W W, CHEN Y Y, et al. Hsp90α Mediates BMI1 expression in breast cancer stem/progenitor cells through facilitating nuclear translocation of c-Myc and EZH2[J]. Int J Mol Sci, 2017, 18(9): 1986. doi: 10.3390/ijms18091986
    [17]
    LEE H W, KIM K M. Clinical significance of heat shock protein 90α expression as a biomarker of prognosis in patients with gastric cancer[J]. Niger J Clin Pract, 2019, 22(12): 1698-1705. doi: 10.4103/njcp.njcp_68_19
    [18]
    WEI W E, LIU M S, NING S F, et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma[J]. BMC Cancer, 2020, 20(1): 6. doi: 10.1186/s12885-019-6489-0
    [19]
    陈莉萍, 曹婷, 李素芬, 等. Hsp90α及SCC在宫颈癌早期诊断及预后监测中的价值[J]. 西部医学, 2020, 12(1): 76-80. doi: 10.3969/j.issn.1672-3511.2020.01.018

    CHEN L P, CAO T, LI S F, et al. The value of Hsp90α and SCC in the early diagnosis and prognosis monitoring of cervical and endocervical cancer[J]. Medical Journal of West China, 2020, 12(1): 76-80. doi: 10.3969/j.issn.1672-3511.2020.01.018
    [20]
    FU Y, XU X, HUANG D S, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: An official, large-scale, and multicenter clinical trial[J]. EBio Medicine, 2017, 24(2): 56-63.
    [21]
    HAN S T, CHENG Z Z, ZHAO X Q, et al. Diagnostic value of heat shock protein 90α and squamous cell carcinoma antigen in detection of cervical cancer[J]. J Int Med Res, 2019, 47(11): 5518-5525. doi: 10.1177/0300060519865634
    [22]
    马庆荣, 余佩芝, 张帆, 等. 热疗中热休克蛋白90对26S蛋白酶体的调控机制[J]. 南方医科大学学报, 2017, 37(4): 537-541. doi: 10.3969/j.issn.1673-4254.2017.04.20

    MA Q R, YU P Z, ZHANG F, et al. The regulation mechanism of heat shock protein 90 on 26S proteasome in hyperthermia[J]. Journal of Southern Medical University, 2017, 37(4): 537-541. doi: 10.3969/j.issn.1673-4254.2017.04.20
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (251) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return